Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies
HE Bays, PB Moore, MA Drehobl, S Rosenblatt… - Clinical …, 2001 - Elsevier
Background: Ezetimibe (SCH 58235) is a novel cholesterol absorption inhibitor that
selectively and potently blocks intestinal absorption of dietary and biliary cholesterol.
Objective: Data from 2 multicenter, placebo-controlled, double-blind, randomized, parallel-
group, 12-week studies of ezetimibe were pooled to evaluate the drug's effect on lipid
parameters in patients with primary hypercholesterolemia. Methods: After dietary
stabilization (National Cholesterol Education Program Step I diet or a stricter diet), washout …
selectively and potently blocks intestinal absorption of dietary and biliary cholesterol.
Objective: Data from 2 multicenter, placebo-controlled, double-blind, randomized, parallel-
group, 12-week studies of ezetimibe were pooled to evaluate the drug's effect on lipid
parameters in patients with primary hypercholesterolemia. Methods: After dietary
stabilization (National Cholesterol Education Program Step I diet or a stricter diet), washout …